Strategic leadership Recent CEO appointment signals a new strategic direction and potential for accelerated business development, making them a prime target for partnerships, licensing conversations, and high-level collaborations with big pharma and biotech firms.

Clinical momentum Lead candidate BO-112 is advancing across multiple trials as monotherapy and in combination with checkpoint inhibitors, presenting collaboration opportunities in trial sponsorship, co-development, and data-sharing arrangements with clinical-stage and large-cap partners.

External collaborations Existing partnerships with Merck & Co and UCLA open doors for co-development, research services, and potential access to external biotech networks for joint programs, technology licensing, and sponsored research avenues.

Financing readiness Recent €15–17.6 million funding round demonstrates investor interest and runway for business development activities, enabling strategic partnerships, market access initiatives, and potential co-financing of clinical programs.

Markets and focus Specialization in immuno-oncology and RNA-based therapies targeting ‘cold’ to ‘hot’ tumor conversion aligns with growing demand for novel combination strategies, presenting opportunities for research collaboration, companion diagnostics, and payer-focused value propositions.